Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 janv. 2024 06h45 HE
|
Liquidia Corporation
MORRISVILLE, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the...
U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)
20 déc. 2023 16h56 HE
|
Liquidia Corporation
Liquidia will pursue final FDA approval for YUTREPIA™ (treprostinil) inhalationLiquidia will immediately request that District Court set aside injunction tied to ‘793 patent MORRISVILLE, N.C., Dec. ...
Liquidia Announces Pricing of Public Offering of Common Stock
12 déc. 2023 07h13 HE
|
Liquidia Corporation
MORRISVILLE, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it has priced an underwritten public offering of 3,491,620 shares of common stock at a...
Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update
07 nov. 2023 06h30 HE
|
Liquidia Corporation
Oral arguments in appeal of ‘793 PTAB decision set for December 4, 2023PDUFA goal date to add PH-ILD indication to YUTREPIA label is January 24, 2024Hired sales force in preparation of potential...
Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023
31 oct. 2023 06h30 HE
|
Liquidia Corporation
MORRISVILLE, N.C., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2023 financial results on Tuesday, November 7, 2023....
FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label
25 sept. 2023 16h09 HE
|
Liquidia Corporation
Sets PDUFA goal date of January 24, 2024If approved, YUTREPIA would be indicated for treatment of both PAH and PH-ILD MORRISVILLE, N.C., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation...
United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office
06 sept. 2023 16h30 HE
|
Liquidia Corporation
Asserts ‘793 patent in new litigation filed under Hatch-Waxman Act in response to Liquidia’s amendment to its NDA to add PH-ILD to YUTREPIA™ labelLitigation is tied to same ‘793 patent previously...
Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update
10 août 2023 06h00 HE
|
Liquidia Corporation
MORRISVILLE, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the second quarter ended June 30, 2023. The...
Liquidia Corporation to Report Second Quarter 2023 Financial Results on August 10, 2023
03 août 2023 08h17 HE
|
Liquidia Corporation
MORRISVILLE, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2023 financial results on Thursday, August 10, 2023....
Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder
27 juil. 2023 06h00 HE
|
Liquidia Corporation
No new clinical data is required to add PH-ILD indication as per FDA correspondenceRecertified that YUTREPIA does not infringe any valid patents listed in the Orange Book for TyvasoPreparing for...